Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$11.6K Hold
483
0.01% 106
2026
Q1
$13.6K Buy
+483
New +$12.9K 0.01% 101
2025
Q1
Sell
-483
Closed -$12.8K 111
2024
Q4
$12.8K Hold
483
0.01% 98
2024
Q3
$14K Hold
483
0.01% 96
2024
Q2
$13.5K Hold
483
0.01% 93
2024
Q1
$13.4K Hold
483
0.01% 93
2023
Q4
$13.9K Sell
483
-3
-0.6% -$91 0.01% 86
2023
Q3
$16.1K Hold
486
0.02% 77
2023
Q2
$17.8K Hold
486
0.02% 74
2023
Q1
$19.8K Hold
486
0.02% 71
2022
Q4
$24.9K Buy
+486
New +$23.3K 0.03% 72

Other funds holding PFE

LAM Group's PFE Position: Q2 2026 in Review

LAM Group held its Pfizer (PFE) position steady in Q2 2026 at 483 shares worth $11.6K. The position accounts for 0.01% of the portfolio, ranked #106.

LAM Group first reported a position in PFE in Q4 2022 and has held it in 11 quarters since. The position peaked at $24.9K in Q4 2022. 1,247 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • LAM Group held 483 shares of Pfizer worth $11.6K as of Q2 2026.
  • LAM Group left its Pfizer share count unchanged in Q2 2026.
  • Pfizer made up 0.01% of LAM Group's portfolio in Q2 2026, its #106 holding.
  • LAM Group first reported a position in Pfizer in Q4 2022 and has held it in 11 quarters since.
  • LAM Group's Pfizer position peaked at $24.9K in Q4 2022.
  • 1,247 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on LAM Group's 13F filing for Q2 2026, filed 10 Jul 2026.